Arcus Biosciences, Inc. (RCUS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 150M 300M 450M FY21: 383M FY22: 112M FY23: 117M FY24: 258M FY25: 247M FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Annual

-450M -300M -150M 0 150M 300M 450M FY21: 54M FY22: -280M FY23: -340M FY24: -330M FY25: -386M FY21 FY22 FY23 FY24 FY25

Net Income Annual

-450M -300M -150M 0 150M 300M 450M FY21: 53M FY22: -267M FY23: -307M FY24: -283M FY25: -353M FY21 FY22 FY23 FY24 FY25

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M FY21: -256M FY22: 438M FY23: -306M FY24: -170M FY25: -482M FY21 FY22 FY23 FY24 FY25

Free Cash Flow Annual

-600M -400M -200M 0 200M 400M 600M FY21: -282M FY22: 432M FY23: -330M FY24: -176M FY25: -484M FY21 FY22 FY23 FY24 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 40M 80M 120M FY21: 74M FY22: 72M FY23: 74M FY24: 90.1M FY25: 107.4M FY21 FY22 FY23 FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q3 '21: -4.15 Q4 '21: 0.71 Q1 '22: 0.83 Q2 '22: 0.99 Q3 '22: 1.20 Q4 '22: -3.72 Q1 '23: -3.85 Q2 '23: -3.96 Q3 '23: -4.00 Q4 '23: -4.15 Q1 '24: -3.11 Q2 '24: -3.09 Q3 '24: -3.15 Q4 '24: -3.10 Q1 '25: -4.19 Q2 '25: -3.17 Q3 '25: -3.44 Q4 '25: -3.31 Q1 '26: -3.19 Q2 '26: -3.91 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.